Brokers Issue Forecasts for Immunocore FY2030 Earnings

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Immunocore in a research report issued on Wednesday, February 4th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $11.26 for the year. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.32. The firm had revenue of $103.69 million during the quarter, compared to analysts’ expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.17 earnings per share.

IMCR has been the subject of several other reports. Morgan Stanley boosted their target price on Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Wells Fargo & Company started coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective for the company. UBS Group set a $55.00 target price on Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, Zacks Research upgraded shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $60.40.

Immunocore Stock Performance

NASDAQ IMCR opened at $32.05 on Thursday. The company has a market cap of $1.62 billion, a P/E ratio of -56.23 and a beta of 0.78. Immunocore has a 1-year low of $23.15 and a 1-year high of $40.71. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The stock has a 50-day moving average of $34.77 and a two-hundred day moving average of $34.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IMCR. Leonteq Securities AG bought a new stake in shares of Immunocore during the fourth quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after buying an additional 311 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after purchasing an additional 1,268 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Immunocore in the second quarter worth $42,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after purchasing an additional 572 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.